These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 3011900)

  • 1. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
    Doebber TW; Wu MS; Biftu T
    J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
    Wu MS; Biftu T; Doebber TW
    J Pharmacol Exp Ther; 1986 Dec; 239(3):841-5. PubMed ID: 3795043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
    J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
    Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X
    Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
    Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
    J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAF and immune complex-induced injury.
    Warren JS; Johnson KJ; Ward PA
    J Lipid Mediat; 1990; 2 Suppl():S229-37. PubMed ID: 1966816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.
    Issekutz AC; Szpejda M
    Lab Invest; 1986 Mar; 54(3):275-81. PubMed ID: 3951199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.
    Hwang SB; Lam MH; Hsu AH
    Mol Pharmacol; 1989 Jan; 35(1):48-58. PubMed ID: 2536468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB; Li CL; Lam MH; Shen TY
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAF, rather than histamine, participates in mouse anaphylactic hypotension.
    Shibamoto T; Liu W; Cui S; Zhang W; Takano H; Kurata Y
    Pharmacology; 2008; 82(2):114-20. PubMed ID: 18583921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the existence and ionic modulation of platelet-activating factor receptors mediating degranulatory responses in human polymorphonuclear leukocytes.
    Marquis O; Robaut C; Cavero I
    J Pharmacol Exp Ther; 1989 Jul; 250(1):293-300. PubMed ID: 2545861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control.
    Longphre M; Kleeberger SR
    Am J Respir Cell Mol Biol; 1995 Nov; 13(5):586-94. PubMed ID: 7576695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney.
    Perico N; Delaini F; Tagliaferri M; Abbate M; Cucchi M; Bertani T; Remuzzi G
    Lab Invest; 1988 Feb; 58(2):163-71. PubMed ID: 3123798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapulmonary tumor necrosis factor triggers local platelet-activating factor production in rat immune complex alveolitis.
    Warren JS; Barton PA; Mandel DM; Matrosic K
    Lab Invest; 1990 Dec; 63(6):746-54. PubMed ID: 2255183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.